Currently ongoing whole-genome sequencing studies are expected to additionally determine the POLD1 mutation rates in tumor entities other than CRC or endometrial cancer, which could then broaden the applicability of the here proposed concept of a novel tumor genotype-based anti-cancer therapy. The gene discussed is POLD1; the disease is cancer.